Operations58Business69Management117Executive Compensation123Certain Relationships and Related Party Transactions127Principal Shareholders131Description of Share Capital133Shares Eligible for Future Sale142Bermuda Company Considerations144Material Bermuda and U.S. Federal Income Tax Considerations150Underwriting156Legal Matters162Experts162Where You Can Find Additional Information162Exchange Controls163Enforcement of Civil Liabilities Under United States Federal Securities Laws164Index to Consolidated Financial StatementsF-1We are responsible for the information contained in this
treatment of female infertility, based on published data evaluating native kisspeptin in women undergoing assisted reproduction.The following chart represents our current product candidate pipeline:1Subject to the submission of our investigational new drug application to the U.S. Food and Drug Administration, or FDA, which we expect to occur in 2016.2Subject to our End of Phase 2 meeting with the FDA, which we expect to occur in the first quarter of 2017.3An End of Phase 2 meeting confirmed that there are no additional clinical trials or nonclinical studies required to support the initiation of a Phase 3 trial.4RVT-602 has been evaluated in Phase 1 and Phase 2a clinical trials conducted by Takeda in men for the treatment of prostate cancer and hypogonadotropic hypogonadism, or
$160.7 million, assuming the common shares are offered at $13.50 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus.We intend to use the net proceeds from this offering primarily for the clinical development of our product candidates, relugolix and RVT-602.
Our ability to generate product revenue depends on a number of factors, including our ability to:•successfully complete clinical trials and obtain regulatory approval for the marketing of relugolix and RVT-602;•set an acceptable price for relugolix and RVT-602 and obtain coverage and adequate reimbursement from third-party payors;•establish sales, marketing and distribution systems for relugolix and RVT-602;•add operational, financial and management information systems and personnel, including personnel to support our clinical, manufacturing and planned
cost levels;•attract and retain an experienced management and advisory team;•achieve broad market acceptance of our products in the medical community and with third party payors and consumers;11Table of Contents•launch commercial sales of our products, whether alone or in collaboration with others; and•maintain, expand and protect our intellectual property portfolio.Because of the numerous risks and uncertainties associated with product development, we are unable to predict
make significant royalty payments in connection with the sale of resulting products.Even with the net proceeds of this offering, we may require additional capital to complete the development and potential commercialization of our product candidates.
management from day-to-day activities and harm our product candidate development efforts.Based upon our current operating plan, we believe that the net proceeds from this offering will enable us to fund our operating expenses and capital expenditure requirements through unblinding and release
Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:•the initiation, progress, timing, costs and results of our planned clinical trials for our product candidates;•the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;•the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;14Table of Contents•the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or the
lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.The use of relugolix and RVT-602 in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the
adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop.Risks Related to Clinical Development, Regulatory Approval and CommercializationClinical trials are very expensive, time-consuming, difficult to design and implement and involve an
Therefore, our ability to compete successfully will depend largely on our ability to:•develop and commercialize medicines that are superior to other products in the market;•demonstrate through our clinical trials that relugolix or RVT-602 is differentiated from existing and future therapies;•attract qualified scientific, product development and commercial personnel;•obtain patent or other proprietary protection for our medicines;•obtain required regulatory approvals;•obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and•successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines.The availability of our
The degree of market acceptance of a product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:•the efficacy and potential advantages compared to alternative treatments;•effectiveness of sales and marketing efforts;•the cost of treatment in relation to alternative treatments, including any similar generic treatments;•our ability to offer our products for sale at competitive prices;•the convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;24Table of Contents•the strength of marketing and distribution support;•the availability of third-party coverage and adequate reimbursement;•the prevalence and severity of any side effects;
We expect that we will be subject to additional risks related to international operations or entering into international business relationships, including:•different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation, or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•foreign reimbursement, pricing and insurance regimes;•foreign taxes;•foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business
maintain the patents and patent applications covering relugolix, RVT-602 or any future product candidate, our competitors might be able to enter the market, which would have an adverse effect on our business.Third party claims or litigation alleging infringement
Forward-looking statements include statements about:•the timing of and our ability to obtain and maintain regulatory approval of relugolix and RVT-602;•our ability to successfully commercialize relugolix and RVT-602, if approved;•the rate and degree of market acceptance of relugolix and RVT-602, if approved;•our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;•our expectation that the net proceeds from this offering will be sufficient to enable us to conduct our planned clinical development of relugolix and